Steven E. Marx

927 total citations
42 papers, 701 citations indexed

About

Steven E. Marx is a scholar working on Hepatology, Epidemiology and Nephrology. According to data from OpenAlex, Steven E. Marx has authored 42 papers receiving a total of 701 indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Hepatology, 14 papers in Epidemiology and 13 papers in Nephrology. Recurrent topics in Steven E. Marx's work include Hepatitis C virus research (21 papers), Parathyroid Disorders and Treatments (13 papers) and Liver Disease Diagnosis and Treatment (11 papers). Steven E. Marx is often cited by papers focused on Hepatitis C virus research (21 papers), Parathyroid Disorders and Treatments (13 papers) and Liver Disease Diagnosis and Treatment (11 papers). Steven E. Marx collaborates with scholars based in United States, United Kingdom and Germany. Steven E. Marx's co-authors include Michael Amdahl, Dennis L. Andress, Raimund Sterz, Joel Z. Melnick, Glen T. Schumock, Stuart M. Sprague, Amie T. Joyce, Kamyar Kalantar‐Zadeh, Mario Cozzolino and Samina Khan and has published in prestigious journals such as Journal of Hepatology, The American Journal of Gastroenterology and American Journal of Kidney Diseases.

In The Last Decade

Steven E. Marx

40 papers receiving 674 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Steven E. Marx United States 16 302 232 222 161 85 42 701
Shahrzad Ossareh Iran 13 269 0.9× 32 0.1× 58 0.3× 30 0.2× 16 0.2× 55 564
Bryn Thompson United States 7 103 0.3× 109 0.5× 92 0.4× 17 0.1× 31 0.4× 9 895
Mukta Mantan India 15 346 1.1× 21 0.1× 62 0.3× 104 0.6× 19 0.2× 70 632
L Sellars United Kingdom 13 267 0.9× 66 0.3× 77 0.3× 22 0.1× 18 0.2× 28 503
Sérgio Gardano Elias Bucharles Brazil 12 308 1.0× 20 0.1× 94 0.4× 94 0.6× 50 0.6× 29 638
Marcelo Santos Sampaio United States 19 159 0.5× 142 0.6× 248 1.1× 69 0.4× 18 0.2× 36 1.3k
Ahmed Mitwalli Saudi Arabia 12 142 0.5× 139 0.6× 146 0.7× 14 0.1× 11 0.1× 33 470
H.S. Wong Malaysia 11 239 0.8× 86 0.4× 42 0.2× 21 0.1× 6 0.1× 43 484
Loke Meng Ong Malaysia 10 250 0.8× 82 0.4× 54 0.2× 29 0.2× 9 0.1× 18 457
Donckerwolcke Ra Netherlands 15 182 0.6× 15 0.1× 38 0.2× 37 0.2× 16 0.2× 30 561

Countries citing papers authored by Steven E. Marx

Since Specialization
Citations

This map shows the geographic impact of Steven E. Marx's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Steven E. Marx with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Steven E. Marx more than expected).

Fields of papers citing papers by Steven E. Marx

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Steven E. Marx. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Steven E. Marx. The network helps show where Steven E. Marx may publish in the future.

Co-authorship network of co-authors of Steven E. Marx

This figure shows the co-authorship network connecting the top 25 collaborators of Steven E. Marx. A scholar is included among the top collaborators of Steven E. Marx based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Steven E. Marx. Steven E. Marx is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Martinez, Anthony, Wei‐Han Cheng, Steven E. Marx, et al.. (2023). Shorter Duration Hepatitis C Virus Treatment is Associated with Better Persistence to Prescription Refills in People Who Inject Drugs: A Real-World Study. Advances in Therapy. 40(8). 3465–3477. 2 indexed citations
2.
Thomas, Emmanuel, et al.. (2021). Awareness and Epidemiology of Chronic Hepatitis C Virus Infections in Florida. Infectious Diseases and Therapy. 11(1). 451–462. 4 indexed citations
3.
Sulkowski, Mark, et al.. (2020). Estimating the Year Each State in the United States Will Achieve the World Health Organization’s Elimination Targets for Hepatitis C. Advances in Therapy. 38(1). 423–440. 27 indexed citations
4.
Flamm, Steven L., Jens Kort, Steven E. Marx, et al.. (2020). Effectiveness of 8-Week Glecaprevir/Pibrentasvir for Treatment-Naïve, Compensated Cirrhotic Patients with Chronic Hepatitis C Infection. Advances in Therapy. 37(5). 2267–2274. 14 indexed citations
5.
Chirikov, Viktor, et al.. (2018). Development of a Comprehensive Dataset of Hepatitis C Patients and Examination of Disease Epidemiology in the United States, 2013–2016. Advances in Therapy. 35(7). 1087–1102. 24 indexed citations
6.
Huber, Caroline, Mark T. Linthicum, Timothy Juday, et al.. (2016). Costs and spillover effects of private insurers' coverage of hepatitis C treatment.. PubMed. 22(6 Spec No.). SP236–44. 5 indexed citations
7.
Linthicum, Mark T., Yuri Sánchez González, Timothy Juday, et al.. (2016). Value of expanding HCV screening and treatment policies in the United States.. PubMed. 22(6 Spec No.). SP227–35. 20 indexed citations
8.
9.
10.
Walker, David, et al.. (2015). Early View of the Effectiveness of New Direct-Acting Antiviral (DAA) Regimens in Patients with Hepatitis C Virus (HCV). Advances in Therapy. 32(11). 1117–1127. 23 indexed citations
11.
12.
Ketteler, Markus, Kévin Martin, Myles Wolf, et al.. (2012). Paricalcitol versus cinacalcet plus low-dose vitamin D therapy for the treatment of secondary hyperparathyroidism in patients receiving haemodialysis: results of the IMPACT SHPT study. Nephrology Dialysis Transplantation. 27(8). 3270–3278. 79 indexed citations
13.
Ketteler, M., Kévin Martin, Mario Cozzolino, et al.. (2011). Paricalcitol versus cinacalcet plus low-dose vitamin D for the treatment of secondary hyperparathyroidism in patients receiving haemodialysis: study design and baseline characteristics of the IMPACT SHPT study. Nephrology Dialysis Transplantation. 27(5). 1942–1949. 25 indexed citations
14.
Schumock, Glen T., Surrey M. Walton, Todd A. Lee, et al.. (2010). Comparative Effectiveness of Paricalcitol versus Cinacalcet for Secondary Hyperparathyroidism in Patients Receiving Hemodialysis. Nephron Clinical Practice. 117(2). c151–c159. 7 indexed citations
15.
Nuijten, Mark, et al.. (2010). Cost Effectiveness of Paricalcitol versus a Non-Selective Vitamin D Receptor Activator for Secondary Hyperparathyroidism in the UK. Clinical Drug Investigation. 30(8). 545–557. 18 indexed citations
16.
Schumock, Glen T., Dennis L. Andress, Steven E. Marx, et al.. (2009). Association of Secondary Hyperparathyroidism with CKD Progression, Health Care Costs and Survival in Diabetic Predialysis CKD Patients. Nephron Clinical Practice. 113(1). c54–c61. 39 indexed citations
17.
McGhan, William F., Maiwenn Al, Jalpa A. Doshi, et al.. (2009). The ISPOR Good Practices for Quality Improvement of Cost-Effectiveness Research Task Force Report. Value in Health. 12(8). 1086–1099. 57 indexed citations
18.
Schumock, Glen T., Dennis L. Andress, Steven E. Marx, et al.. (2008). Impact of secondary hyperparathyroidism on disease progression, healthcare resource utilization and costs in pre-dialysis CKD patients. Current Medical Research and Opinion. 24(11). 3037–3048. 33 indexed citations
19.
Bergemann, R, et al.. (2006). Health-Economic Comparison of Paricalcitol, Calcitriol and Alfacalcidol for the Treatment of Secondary Hyperparathyroidism during Haemodialysis. Clinical Drug Investigation. 26(11). 629–638. 12 indexed citations
20.
Roth, W. Kurt, Steven E. Marx, S Zeuzem, et al.. (1997). Prevalence of hepatitis G virus and its strain variant, the GB agent, in blood donations and their transmission to recipients. Transfusion. 37(6). 651–656. 59 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Shahrzad Ossareh Breakdown of academic impact, for papers by Bryn Thompson Breakdown of academic impact, for papers by Mukta Mantan Breakdown of academic impact, for papers by L Sellars Breakdown of academic impact, for papers by Sérgio Gardano Elias Bucharles Breakdown of academic impact, for papers by Marcelo Santos Sampaio Breakdown of academic impact, for papers by Ahmed Mitwalli Breakdown of academic impact, for papers by H.S. Wong Breakdown of academic impact, for papers by Loke Meng Ong Breakdown of academic impact, for papers by Donckerwolcke Ra
Rankless by CCL
2026